The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.
 
Jerome Galon
Stock and Other Ownership Interests - HalioDx
Honoraria - HalioDx
Consulting or Advisory Role - Actelion; Amgen; AstraZeneca; Biotherapeutics; Bristol-Myers Squibb; Compugen; Definiens; GlaxoSmithKline; HalioDx; Illumina; ImmunID Technologies; IO Biotech; Kite, a Gilead company; MedImmune; Merck Serono; MOLOGEN; NanoString Technologies; Northwest Biotherapeutics; Novartis; Roche
Research Funding - AstraZeneca; Janssen; MedImmune; Perkin Elmer
Patents, Royalties, Other Intellectual Property - INSERM
 
Fabienne Hermitte
Employment - HalioDx
Stock and Other Ownership Interests - HalioDx
 
Bernhard Mlecnik
Patents, Royalties, Other Intellectual Property - INSERM
 
Florence Marliot
No Relationships to Disclose
 
Carlo Bruno Bifulco
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - 32898 US2 - U.S. Patent Application No. 15/910972 filed March 2, 2018
 
Alessandro Lugli
Honoraria - 3DHISTECH; Sakura Finetek Japan; Sysmex
Consulting or Advisory Role - Amgen
 
Iris D. Nagtegaal
No Relationships to Disclose
 
Arndt Hartmann
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Sysmex
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - BioNTech; Janssen; NanoString Technologies; Novartis; Roche
Expert Testimony - NanoString Technologies
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Sysmex
 
Marc Van Den Eynde
No Relationships to Disclose
 
Michael H. A. Roehrl
Consulting or Advisory Role - Gerson Lehrman Group; Proscia; Trans-Hit Bio
 
Pamela S Ohashi
No Relationships to Disclose
 
Eva Zavadova
No Relationships to Disclose
 
Toshihiko Torigoe
No Relationships to Disclose
 
Prabhudas S. Patel
No Relationships to Disclose
 
Yili Wang
No Relationships to Disclose
 
Yutaka Kawakami
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Francesco Marincola
Employment - Abbvie
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Bernard A. Fox
Employment - UbiVac; UbiVac (I)
Leadership - UbiVac
Stock and Other Ownership Interests - PrimeVax; UbiVac
Honoraria - Janssen Biotech; Nodality
Consulting or Advisory Role - Bayer; Celldex; Definiens; MedImmune
Research Funding - Bristol-Myers Squibb; DEfiniens; Janssen Biotech; MedImmune (Inst); Perkin Elmer; Viralytics
Patents, Royalties, Other Intellectual Property - Patent around the DPV-001 cancer vaccine. This patent is owned by the Providence Health System and licensed to UbiVac
 
Franck Pages
Research Funding - HalioDx
Patents, Royalties, Other Intellectual Property - INSERM